Evidence map›Paper›PMID 40182046›Full record

ArticleFrontiers in oncology2025

Alpha-synuclein knockout impairs melanoma development and alters DNA damage repair in the TG3 mouse model in a sex-dependent manner.

Moriah R Arnold, Suzie Chen, Vivek K Unni

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Moriah R ArnoldMedical Scientist Training Program, Oregon Health and Science University, Portland, OR, United States.
Suzie ChenDepartment of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States.
Vivek K UnniDepartment of Neurology and Jungers Center for Neurosciences Research, Oregon Health and Science University, Portland, OR, United States.

Funding

Ultrastructure and Single Particle Microscopy CoreP30NS061800 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI AICHER, SUE A · 2009 to 2020
$6.6M
CHRONIC MYELOGENOUS LEUKEMIA AND BCR-ABL SUBSTRATESR01CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 1995 to 2021
$4.7M
Mechanisms of Neurodegeneration in Lewy Body DisordersR01NS102227 · NINDS · OREGON HEALTH & SCIENCE UNIVERSITY · PI UNNI, VIVEK · 2017 to 2021
$1.9M
Chronic Myelogenous Leukemia and BCR-ABL SubstratesR37CA065823 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI DRUKER, BRIAN J · 2011 to 2015
$1.5M
The role of alpha-synuclein in nucleolar DNA double-strand break repair and cellular senescenceF30AG082406 · NIA · OREGON HEALTH & SCIENCE UNIVERSITY · PI Moriah Rebecca Arnold · 2023 to 2026
$216k
BLRD VA I01 BX003742BLRD VA IK6 BX006319NCI NIH HHS R01 CA065823NCI NIH HHS R37 CA065823NIA NIH HHS F30 AG082406NINDS NIH HHS P30 NS061800NINDS NIH HHS R01 NS102227
6 · The paper itself

Abstract

Introduction: Strong evidence suggests links between Parkinson's Disease (PD) and melanoma, as studies have found that people with PD are at an increased risk of developing melanoma and those with melanoma are at increased risk of developing PD. Although these clinical associations are well-established, the cellular and molecular pathways linking these diseases are poorly understood. Recent studies have found a previously unrecognized role for the neurodegeneration-associated protein alpha-synuclein (αSyn) in melanoma; the overexpression of αSyn promotes melanoma cell proliferation and metastasis. However, to our knowledge, no studies have investigated the role of αSyn in Methods: Our study created and characterized Snca knockout in the spontaneously developing melanoma TG3 mouse line, TG3+/+ Results: We show that αSyn loss-of-function significantly delays melanoma onset and slows tumor growth Discussion: Overall, our study may suggest that targeting αSyn and its role in modulating the DDR and melanomagenesis could serve as a promising new therapeutic target.

Indexed as

alpha-synucleinDNA damage responsedouble strand break (DSB)melanomaParkinson’s disease

Identifiers

PMID40182046
PMCPMC11967197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.